Skip to main content
Top
Published in: Virchows Archiv 3/2006

01-09-2006 | Original Article

Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure

Authors: Anna Sapino, Caterina Marchiò, Rebecca Senetta, Isabella Castellano, Luigia Macrì, Paola Cassoni, Giampiero Ghisolfi, Milena Cerrato, Enrico D’Ambrosio, Gianni Bussolati

Published in: Virchows Archiv | Issue 3/2006

Login to get access

Abstract

We propose multicore tissue microarray (TMA) as an alternative to whole section for routine assessment of prognostic factors in breast cancer. Since 2004, we introduced the multicore TMA for testing estrogen (ER) and progesterone receptors (PR), proliferation activity by Ki67, and HER2 overexpression and amplification in routine work. At least four tumor foci were selected on the whole section, and a dedicated technician used a stereomicroscope for accurate sampling of the selected areas. To identify a specific case in the TMA, a separate file and a computerized reporting form with the TMA map were created. A preliminary pilot study comparing the TMA results with those obtained on whole sections showed the specificity of the procedure. Moreover, in everyday diagnosis, hormone receptors were repeated on full section when negative in TMA, without significant discrepancy. Retrospective analysis of the 237 breast carcinomas studied by TMA showed the expected correspondence of tumor-grade differentiation with the hormone receptor pattern, the proliferation activity, and HER2 immunohistochemical and FISH values. In conclusion, multicore TMA may be an efficient approach in the routine study of prognostic factors in breast cancer, significantly reducing costs, time, and burden of slides necessary to accomplish these mandatory tests.
Literature
1.
go back to reference Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116:340–350PubMedCrossRef Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116:340–350PubMedCrossRef
2.
go back to reference Bhargava R, Lal P, Chen B (2004) Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma. Diagn Mol Pathol 13:213–216PubMedCrossRef Bhargava R, Lal P, Chen B (2004) Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma. Diagn Mol Pathol 13:213–216PubMedCrossRef
3.
go back to reference Bubendorf L, Nocito A, Moch H, Sauter G (2001) Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 195:72–79PubMedCrossRef Bubendorf L, Nocito A, Moch H, Sauter G (2001) Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 195:72–79PubMedCrossRef
4.
go back to reference Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest 80:1943–1949PubMedCrossRef Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest 80:1943–1949PubMedCrossRef
5.
go back to reference Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412:822–826PubMedCrossRef Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412:822–826PubMedCrossRef
6.
go back to reference Ellis IO, Bartlett J, Dowsett M, Humphreys S, Jasani B, Miller K, Pinder SE, Rhodes A, Walker R (2004) Updated recommendations for HER2 testing in the UK. J Clin Pathol 57:233–237PubMedCrossRef Ellis IO, Bartlett J, Dowsett M, Humphreys S, Jasani B, Miller K, Pinder SE, Rhodes A, Walker R (2004) Updated recommendations for HER2 testing in the UK. J Clin Pathol 57:233–237PubMedCrossRef
7.
go back to reference Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef
8.
go back to reference Gillett CE, Springall RJ, Barnes DM, Hanby AM (2000) Multiple tissue core arrays in histopathology research: a validation study. J Pathol 192:549–553PubMedCrossRef Gillett CE, Springall RJ, Barnes DM, Hanby AM (2000) Multiple tissue core arrays in histopathology research: a validation study. J Pathol 192:549–553PubMedCrossRef
9.
go back to reference Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ; Panel members (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583PubMedCrossRef Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ; Panel members (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583PubMedCrossRef
10.
go back to reference Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of hundreds of specimens. Nat Med 4:844–847PubMedCrossRef Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of hundreds of specimens. Nat Med 4:844–847PubMedCrossRef
11.
go back to reference Lal P, Tan LK, Chen B (2005) Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 123:541–546PubMedCrossRef Lal P, Tan LK, Chen B (2005) Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 123:541–546PubMedCrossRef
12.
go back to reference Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, Adamson R, Rhodes T, Miller K, Walker R (2000) Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The scottish breast cancer pathology group, and the receptor and biomarker study group of the eortc. J Clin Pathol 53:634–635PubMedCrossRef Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, Adamson R, Rhodes T, Miller K, Walker R (2000) Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The scottish breast cancer pathology group, and the receptor and biomarker study group of the eortc. J Clin Pathol 53:634–635PubMedCrossRef
13.
go back to reference Moch H, Kononen T, Kallioniemi OP, Sauter G (2001) Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol 8:14–20PubMedCrossRef Moch H, Kononen T, Kallioniemi OP, Sauter G (2001) Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol 8:14–20PubMedCrossRef
14.
go back to reference Nocito A, Kononen J, Kallioniemi OP, Sauter G (2001) Tissue microarrays (TMAs) for high throughput molecular pathology research. Int J Cancer 94:1–5PubMedCrossRef Nocito A, Kononen J, Kallioniemi OP, Sauter G (2001) Tissue microarrays (TMAs) for high throughput molecular pathology research. Int J Cancer 94:1–5PubMedCrossRef
15.
go back to reference Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J (2004) Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 17:790–797PubMedCrossRef Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J (2004) Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 17:790–797PubMedCrossRef
16.
go back to reference Rubin MA, Dunn R, Strawderman M, Pienta KJ (2002) Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26:312–319PubMedCrossRef Rubin MA, Dunn R, Strawderman M, Pienta KJ (2002) Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26:312–319PubMedCrossRef
17.
go back to reference Sapino A, Coccorullo Z, Cassoni P, Ghisolfi G, Gugliotta P, Bongiovanni M, Arisio R, Crafa P, Bussolati G (2003) Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains. Histopathology 43:354–362PubMedCrossRef Sapino A, Coccorullo Z, Cassoni P, Ghisolfi G, Gugliotta P, Bongiovanni M, Arisio R, Crafa P, Bussolati G (2003) Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains. Histopathology 43:354–362PubMedCrossRef
18.
go back to reference Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159:2249–2256PubMed Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159:2249–2256PubMed
19.
go back to reference Zhang D, Salto-Tellez M, Putti TC, Do E, Koay ES (2003) Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 16:79–84PubMedCrossRef Zhang D, Salto-Tellez M, Putti TC, Do E, Koay ES (2003) Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 16:79–84PubMedCrossRef
20.
go back to reference Zhang D, Salto-Tellez M, Do E, Putti TC, Koay ES (2003) Evaluation of HER2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 34:362–368PubMedCrossRef Zhang D, Salto-Tellez M, Do E, Putti TC, Koay ES (2003) Evaluation of HER2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 34:362–368PubMedCrossRef
Metadata
Title
Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure
Authors
Anna Sapino
Caterina Marchiò
Rebecca Senetta
Isabella Castellano
Luigia Macrì
Paola Cassoni
Giampiero Ghisolfi
Milena Cerrato
Enrico D’Ambrosio
Gianni Bussolati
Publication date
01-09-2006
Publisher
Springer-Verlag
Published in
Virchows Archiv / Issue 3/2006
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-006-0233-2

Other articles of this Issue 3/2006

Virchows Archiv 3/2006 Go to the issue